SecBot SecBot
PRESS-RELEASE ·Filed May 13, 2026

RVPH

Reviva Pharmaceuticals
BEARISH
Impact 7/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The Nasdaq-to-OTCQB transition is a material negative catalyst that will reduce liquidity and institutional interest. Monitor for FDA feedback in mid-2026 as the only near-term binary event. The $22.2M cash position provides runway into late 2026, but the OTCQB listing makes follow-on financing more dilutive.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.3900
T+0 close · May 13, 2026 · via day close
Latest settled
+10.33%
T+60 · $0.4303
Vs SPY
+6.74%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $0.3900entry
  2. T+1 · 6mo ago 0.00%α −0.01% · $0.3900
  3. T+5 · 6mo ago +7.55%α +8.26% · $0.4194
  4. T+20 · 5mo ago +75.36%α +76.22% · $0.6839
  5. T+60 · 3mo ago +10.33%α +6.74% · $0.4303
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Reviva Pharmaceuticals reported Q1 2026 net loss of $3.2M ($0.46/share), narrower than the year-ago $6.4M loss ($2.61/share), but the EPS of -$0.46 missed the consensus estimate of -$0.29 by 58.6%. The company is advancing its brilaroxazine program with FDA feedback expected mid-2026 and RECOVER-2 Phase 3 enrollment in Q3 2026, but its stock is transitioning from Nasdaq to OTCQB effective May 14, 2026, which severely limits liquidity and access to capital.

Key Financial Metrics

EPS
−$0.46
est −$0.29 · -58.6%
Rating
miss

Key Facts

  • Q1 2026 net loss of $3.2M ($0.46/share) vs $6.4M ($2.61/share) in Q1 2025
  • EPS of -$0.46 missed consensus estimate of -$0.29 by 58.6%
  • Cash and equivalents $22.2M as of March 31, 2026, up from $14.4M at year-end 2025
  • Common stock transitioning from Nasdaq to OTCQB effective May 14, 2026
  • Completed $10M public equity offering in March 2026
  • FDA feedback on new brilaroxazine form expected mid-2026; RECOVER-2 Phase 3 enrollment expected Q3 2026

Financial Impact

EPS miss of 58.6% vs consensus; net loss improved YoY but still significant burn rate of ~$3.2M/quarter

epscashdilution

Risk Factors

  • OTCQB listing severely limits liquidity and institutional ownership
  • Cash burn of ~$3.2M/quarter with no revenue; may require dilutive financing
  • FDA feedback on brilaroxazine form is binary and could delay RECOVER-2 trial

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3294478

Track record

12 reports on RVPH

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +22.98% at T+20 after the Jul 10, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 3/10 No price data
  2. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.3400 Now $0.3504 +3.07% settles Feb 11
  3. Nov 9, 20267d ago DEF 14A Neutral 4/10 Entry $0.3521 Now $0.3504 −0.47% settles Feb 8
  4. Aug 12, 202613w ago Press Release Neutral 4/10 Entry $0.3521 to $0.3521 Now $0.3504 −0.47% · 0.00% +5.48% vs SPY
  5. Jul 10, 202618w ago 25-NSE Bearish 7/10 Entry $0.6200 to $0.5000 Now $0.3504 +43.48% ▲ +19.35% +22.24% vs SPY
  6. May 13, 202626w ago Press Release Bearish 7/10 Viewing Entry $0.3900 to $0.4303 Now $0.3504 +10.14% ▼ −10.33% −6.74% vs SPY
  7. May 13, 202626w ago 8-K Bearish 8/10 Entry $0.3521 to $0.4775 Now $0.3504 +0.47% ▼ −35.62% −31.19% vs SPY
  8. Apr 15, 202630w ago 8-K Neutral 5/10 Entry $0.8900 to $0.5731 Now $0.3504 −60.62% ▼ −35.61% −43.74% vs SPY
  9. Mar 30, 202633w ago Press Release Mixed 6/10 Entry $0.6600 to $0.6000 Now $0.3504 −46.90% ▼ −9.09% −25.58% vs SPY
  10. Mar 18, 202634w ago Press Release Bearish 6/10 Entry $0.8300 to $0.7000 Now $0.3504 +57.78% ▲ +15.66% +30.01% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (11h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026